Market Trends of Cell Counting Industry
This section covers the major market trends shaping the Cell Counting Market according to our research experts:
The Instruments Segment is Expected to Hold a Significant Share Over the Forecast Period.
The instruments segment is expected to hold a significant share over the forecast period due to factors such as the increasing usage of cell counters in various applications like research, diagnostics, and industrial. Cell counting instruments are increasingly being adopted in various research areas, such as cancer biology, immunology, and neuroscience, which displays exponential growth opportunities for the market segment.
According to the study published by PubMed Central in November 2021, a new cell counter called RapID Cell Counter was analyzed. It is a semi-automated cell-counting tool with an easy-to-implement graphical user interface (GUI), and it is able to facilitate quick and consistent quantifications of cell density within user-defined boundaries that can be divided into equally partitioned segments. The importance and efficiency of cell counter instruments will lead to increased demand for these instruments, which is expected to propel the instrument segment's growth over the coming years.
Furthermore, rising initiatives from the key market players to launch advanced cell counter devices have led to increased adoption of these devices due to their diverse applications and ease of workflow. For instance, in June 2021, CytoSMART Technologies introduced one of the first fluorescent cell counters. The CytoSMART Exact FL is a fully automated dual fluorescence cell counter with artificial intelligence (AI)-powered image recognition algorithms.The rise in product advancements will lead to higher adoption, thereby driving this segment's growth. Moreover, the rising prevalence of cancer is one of the major factors driving the growth of the segment, as cell counters are being increasingly used in oncology.
Therefore, due to factors such as increasing adoption in various research areas, such as cancer biology, immunology, and neuroscience, and rising initiatives from the key market players to launch advanced cell counter devices, the instruments segment is expected to experience growth over the forecast period.
North America Holds a Significant Share in the Market and is Expected to do Same in the Forecast Period
North America holds a significant share of the market and is expected to do the same in the overall cell counting market throughout the forecast period. The large share of the market is mostly due to the fact that there are more patients, more healthcare settings are using high-throughput flow cytometry and automated hematology analyzers, and key players are based in the region.
The United States holds a significant market share in the North American region due to factors such as the increasing number of chronic diseases and the growing number of research and development activities in the country. According to the American Cancer Society's 2022 statistics, in the United States, there will be 290,560 new cases of breast cancer, 268,490 new cases of prostate cancer, and 236,740 new cases of lung and bronchial cancer in 2022. Such a high burden of cancer creates the need for a proper diagnosis and thus drives the growth of the market in the region.
Furthermore, according to the data published by the Canadian Cancer Society in November 2022, an estimated 233,900 people will be diagnosed with cancer in 2022. This growth in incidence is mainly due to Canada's growing and aging population and emphasizes the importance of cancer prevention. The high prevalence of cancer in Canada is also expected to increase the demand for cell counters, thus driving the market's growth.
Furthermore, the rise in product launches by companies in the United States will further lead to increased adoption of these devices, thereby propelling the growth of this market in North America. For instance, in August 2021, BD (Becton, Dickinson, and Company), a United States-based medical devices company, launched a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes.
Therefore, owing to the above factors, such as the rise in product launches by companies and the increasing prevalence of diseases like cancer in the region, the North American region is expected to show significant growth over the forecast period.
